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Hepatitis C is a highly prevalent chronic viral infection 
which poses major public health, economic and social 
crises, particularly in low and middle income countries. 
The global hepatitis C epidemic has been described by 
the World Health Organization as a ‘viral time bomb’, yet 
continues to receive little attention. Access to preventative 
services is far too low, while diagnosis and treatment are 
prohibitively expensive and remain inaccessible for most 
people in need. Public awareness and political will with 
regard to hepatitis C are also too low, and national hepatitis 
surveillance is often non-existent. 
The hepatitis C virus is highly infectious and is easily 
transmitted through blood-to-blood contact. It therefore 
disproportionately impacts upon people who inject drugs: 
of the 16 million people who inject drugs around the  
world, an estimated 10 million are living with hepatitis C.  
In some of the countries with the harshest drug policies, 
the majority of people who inject drugs are living with 
hepatitis C – more than 90 percent in places such as 
Thailand and parts of the Russian Federation.
The hepatitis C virus causes debilitating and fatal disease 
in around a quarter of those who are chronically infected, 
and is an increasing cause of premature death among 
people who inject drugs. Globally, most HIV-infected 
people who inject drugs are also living with a hepatitis C 
infection. Harm reduction services – such as the provision 
of sterile needles and syringes and opioid substitution 
therapy – can effectively prevent hepatitis C transmission 
among people who inject drugs, provided they are 
accessible and delivered at the required scale. 
EXECUTIVE SUMMARY
Instead of investing in effective prevention and 
treatment programmes to achieve the required coverage, 
governments continue to waste billions of dollars 
each year on arresting and punishing drug users – a 
gross misallocation of limited resources that could be 
more efficiently used for public health and preventive 
approaches. At the same time, repressive drug policies 
have fuelled the stigmatisation, discrimination and mass 
incarceration of people who use drugs. As a result, there 
are very few countries that have reported significant 
declines in new infections of hepatitis C among this 
population. This failure of governments to prevent and 
control hepatitis disease has great significance for future 
costs to health and welfare budgets in many countries. 
In 2012 the Global Commission on Drug Policy released 
a report that outlined how the ‘war on drugs’ is driving 
the HIV epidemic among people who use drugs. The 
present report focuses on hepatitis C as it represents 
another massive and deadly epidemic for this population. 
It provides a brief overview of the hepatitis C virus, before 
exploring how the ‘war on drugs’ and repressive drug 
policies are failing to drive transmission down.
The silence about the harms of repressive drug policies 
has been broken – they are ineffective, violate basic human 
rights, generate violence, and expose individuals and 
communities to unnecessary risks. Hepatitis C is one of 
these harms – yet it is both preventable and curable when 
public health is the focus of the drug response. Now is the 
time to reform.
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1. Governments should publicly acknowledge the 
importance of the hepatitis C epidemic and its 
significant human, economic and social costs, 
particularly among people who use drugs.
2. Governments must acknowledge that drug policy 
approaches dominated by strict law enforcement 
practices perpetuate the spread of hepatitis C  
(as well as HIV and other health harms). They do  
this by exacerbating the social marginalisation  
faced by people who use drugs, and by undermining 
their access to essential harm reduction and 
treatment services. 
3. Governments should therefore reform existing 
drug policies – ending the criminalisation and mass 
incarceration of people who use drugs, and the 
forced treatment of drug dependence. 
4. Governments must immediately redirect resources 
away from the ‘war on drugs’ and into public health 
approaches that maximise hepatitis C prevention 
and care, developed with the involvement of, the 
most affected communities. 
5. Drug policy effectiveness should be measured by 
indicators that have real meaning for affected 
communities, such as reduced rates of HIV and 
hepatitis transmission and mortality, increased 
service coverage and access, reduced drug market 
violence, reduced human rights violations, and 
reduced incarceration.
6. Governments must remove any legal or de facto 
restrictions on the provision of sterile injection 
equipment and other harm reduction services, as 
well as opioid substitution therapy, in line with  
World Health Organisation guidance. It is critical 
that these services are delivered at the scale 
required to impact upon hepatitis C transmission – 
both in the community but also in prisons and other 
closed settings.
7. Governments should ensure that people who use 
drugs are not excluded from treatment programmes, 
by establishing national hepatitis C strategies and 
action plans with the input of civil society, affected 
communities, and actors from across the HIV, public 
health, social policy, drug control and criminal 
justice sectors.
8. Governments must improve the quality and 
availability of data on hepatitis C, strengthening 
surveillance systems and better evaluating 
prevention and control programmes. This will, in 
turn, help to raise political and public awareness of 
the epidemic. 
9. Governments should enhance their efforts to reduce 
the costs of new and existing hepatitis C medicines – 
including through negotiations with pharmaceutical 
companies to ensure greater treatment access 
for all those in need. Governments, international 
bodies and civil society organisations should seek to 
replicate the successful reduction in HIV treatment 
costs around the world, including the use of patent 
law flexibilities to make them more accessible. 
10. The Global Commission calls upon the United 
Nations to demonstrate the necessary leadership 
and commitment to promote better national 
responses and achieve the reforms listed above. 
11. Act urgently: The ‘war on drugs’ has failed, and 
significant public health harms can be averted if 
action is taken now.
 MAIN RECOMMENDATIONS
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 There are an estimated 16 million people who inject 
drugs around the world,1 and around 10 million of 
them are affected by hepatitis C.2 This epidemic is 
growing rapidly in many regions of the world, driven 
by ineffective and repressive drug policies and posing 
major economic and social threats to countries. The 
hepatitis C virus is transmitted through blood-to-blood 
contact. It can be prevented among people who use 
drugs when proven harm reduction interventions 
(such as the provision of sterile needles and syringes) 
are delivered at the required scale. Hepatitis C is 
also curable, yet very few people are able to access 
treatment due to its prohibitive costs. For people who 
use drugs, access to prevention or treatment are 
further decreased by criminalisation, imprisonment and 
systematic discrimination – including reluctance from 
some health care providers to offer treatment. 
 Epidemiology
 Hepatitis C is more than three times more prevalent 
among people who inject drugs than HIV.1,2 The largest 
numbers of hepatitis C infections among this population 
are reported in East and Southeast Asia (2.6 million 
people), and in Eastern Europe (2.3 million people).  
The three countries with the highest hepatitis C burden 
among people who inject drugs are China (1.6 million 
people), the Russian Federation (1.3 million people) and 
the USA (1.5 million people).2 
 In most countries, more than half the people who 
inject drugs are living with hepatitis C.3,4 Infection rates 
are particularly high in many countries whose drug 
policies and law enforcement practices restrict access 
to sterile needles and syringes. In Thailand and parts of 
the Russian Federation, for example, up to 90 percent 
of people who inject drugs have tested positive for 
hepatitis C.5 The rate of new hepatitis C infections 
among people who inject drugs is often above  
10 percent per year6 – but can be substantially higher  
in some countries: in a study from the USA, more  
than half of those who recently started injecting  
were infected.7
 Crucially, the true size of this epidemic is likely 
underestimated as most countries have insufficient 
surveillance data.8,9 Increased efforts to build 
comprehensive, coordinated surveillance systems  
to monitor hepatitis infections are needed as a 
foundation for the scale-up of effective prevention  
and control services.10
 HEPATITIS C AMONG PEOPLE  
WHO USE DRUGS
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Sharing needles and syringes to inject drugs is the the most common risk 
factor for contracting the hepatitis C virus. 
© Lorena Ros for the Open Society Foundations
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 One major consequence of the ‘war on drugs’ is the  
wide-scale incarceration of people who use drugs.  
At the same time, injecting drug use in prisons remains 
widespread. The absence of sterile injecting (and 
tattooing) equipment, and the lack of opioid substitution 
treatment and hepatitis services in most prisons and 
pre-trial detention settings11 makes incarceration an 
independent risk factor for hepatitis C infection among 
people who use drugs.12
 In many countries, hepatitis C is more common in 
prisons than in the general population.13 As a result, the 
provision of testing and treatment to prisoners has been 
shown to be a cost-effective strategy.14 The provision 
of sterile injecting equipment, opioid substitution 
therapy and drug treatment in all closed settings is 
also recommended by the World Health Organization. 
Contrary to common beliefs, it has been shown that 
needle and syringe distribution in closed settings has  
no negative impact on the security of prison staff,  
and (as in community settings) it does not increase 
injecting drug use.15,16 A recent survey in Scotland found 
lower rates of hepatitis C infection among prisoners 
who inject drugs than in the community – linked to 
the wide-scale availability and high coverage of opioid 
substitution therapy inside prisons.17
 The USA has one of the world’s largest prison 
populations for drug offences, and the level of hepatitis 
C infection amongst US prisoners is substantially 
higher than in the general population: between 12 and 
35 percent of prison inmates are infected with hepatitis 
C, compared to between 1 and 2 percent of the general 
population. Despite the evidence of effectiveness, the 
US Center for Disease Control and Prevention (CDC) 
does not recommend needle and syringe programmes in 
prisons,18 and the coverage of hepatitis C testing and 
treatment in US prisons is poor.19,20
 HOW THE INCARCERATION OF PEOPLE WHO USE DRUGS 
FUELS THE HEPATITIS C EPIDEMIC
FIGURE 1. 
THE PREVALENCE 
OF HEPATITIS C 
ANTIBODIES AMONG 
PEOPLE WHO  
INJECT DRUGS2
Note: The prevalence data in 
this map provide cumulative 
information on infections over  
the last decades. High prevalence 
rates on this map therefore may 
not indicate high rates of new 
infections. Data on new hepatitis 
C infections (also known as 
‘incidence’) is unavailable in  
most countries. 
No evidence of injecting drug use 
No eligible report (74 countries) 
<40% (16 countries) 
40 - <60% (24 countries) 
60 - <80% (25 countries) 
>80% (12 countries)
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 Transmission
 The risk of contracting hepatitis C when sharing 
injection equipment is significantly higher than for HIV 
due to the hepatitis C virus’s greater infectivity.21 This 
fact, together with the high prevalence of hepatitis 
C, explains why this particular epidemic spreads so 
fast among people who inject drugs. The hepatitis C 
virus survives for a significant period of time outside 
the body – in needles and syringes,22 but also in other 
injecting equipment such as filters and water used for 
injections.23 This may also partially explain why new 
hepatitis C infections are not decreasing as fast as new 
HIV infections in some countries that have established 
harm reduction programmes. The coverage of these 
programmes needs to be much higher in most countries 
in order to impact upon hepatitis C transmission: even 
if people who inject drugs use sterile equipment the 
majority of times, just a few high-risk injections per 
year can sustain the epidemic.24 This scale-up requires 
strong political commitment and supportive policies, 
including the shift of resources away from the ‘war on 
drugs’ and into public health approaches.
 In higher income countries, injecting drug use has been 
the primary mode of hepatitis C transmission for several 
decades – accounting for between 50 and 80 percent 
of all new hepatitis C infections.25 Due to its high 
potential for transmission, it has also been hypothesised 
that the hepatitis C virus could be spread by sharing 
non-injection drug use equipment such as straws 
and pipes,26 while non-sterile tattooing and piercing 
practices can also lead to infections. Contaminated 
medical equipment and blood transfusions may 
also account for significant numbers of infections in 
countries with weak health infrastructures and blood 
testing capacities.
6
 Mortality and Morbidity
 Hepatitis C is the world’s leading cause of liver disease: 
for 80 percent of those living with the virus, their 
infection takes a chronic course.27 The virus causes fatal 
liver disease in around a quarter of those with chronic 
infections. However, hepatitis C infections can present 
no, or only mild, symptoms for several years – so the 
majority of people are not aware of their condition 
(hence the virus’s label as the “silent epidemic”28). 
In many cases, chronic hepatitis C infections remain 
undetected until advanced liver damage has occurred.
 The risk of liver cirrhosis and liver cancer increases with 
age and will progress quicker in the presence of high 
alcohol intake, HIV infection, illicit drug use and the 
long-term use of psychiatric medications. As a result, 
people who use drugs and who are living with hepatitis 
C have a particularly heightened risk of liver cirrhosis, 
liver cancer and liver-related death.29,30
 Hepatitis C is an increasing cause of early deaths 
among people who inject drugs.31 Between 1999 and 
2007, more people in the USA died from hepatitis C 
than from HIV.32 Between the age of 45 and 50, the risk 
of developing liver cirrhosis rises sharply in hepatitis 
C-infected people who inject drugs.30 The global burden 
of advanced hepatitis C-related liver disease is growing, 
and will continue to grow among people who use drugs 
– with clear implications for public health and public 
spending. Hepatitis C is a global public health crisis: the 
World Health Organization has referred to it as ‘the viral 
time bomb’.33
2013 GCDP REPORT
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 Approximately 3 million people who inject drugs  
are living with HIV, and most of these individuals are 
also living with hepatitis C infections.34 In China,  
the Russian Federation and Vietnam, for example, co-
infection rates among HIV-infected people  
who inject drugs are estimated to be more than  
90 percent.35 Since the vast majority of co-infected 
individuals are people who inject drugs,36 the 
twin epidemics of HIV and hepatitis C are fuelled 
by policies that increase risk, impede access to 
prevention services, and drive vulnerable people away 
from health services. Importantly, preventive efforts 
delivered at the scale needed to prevent hepatitis C 
transmission among people who inject drugs will also 
be able to prevent HIV transmission.
 Hepatitis C disease progression, survival outcomes 
and treatment success are all negatively influenced 
by HIV co-infection.37 At the same time, treatment 
uptake remains unacceptably low for co-infected 
individuals, even those who are receiving HIV care38 – 
yet hepatitis C treatment has been shown to increase 
adherence to HIV treatment among this population.39 
In addition, very few people who use drugs have been 
enrolled into clinical trials on HIV and hepatitis C 
co-infection treatment, and this needs to be urgently 
rectified in order to further improve treatment 
outcomes for these individuals.
 Hepatitis B is another viral infection and, like hepatitis 
C, it is transmitted primarily through blood-to-blood 
contact. The routes of transmission for hepatitis B are 
broader: including from mother to child, person to person 
in early childhood, unsafe medical procedures, and 
higher-risk sexual practices, as well as the sharing of 
contaminated equipment by people who inject drugs. In 
adults, the chance of developing a chronic infection  
is less than 5 percent. 
 HIV/HEPATITIS C CO-INFECTION
 HEPATITIS B
 People at risk of hepatitis C infection should be regularly 
tested to determine if they are contagious or in need of 
treatment. However, the number of undiagnosed cases is 
estimated to be very high: between 50 and 90 percent 
of people living with hepatitis C may be unaware of their 
infection.49,50 In countries with repressive drug laws, 
hepatitis C testing rates among people who use drugs 
are often even lower10,51 – largely due to stigmatisation in 
health care settings, fear of arrest, or the unavailability  
of treatment and testing.
 The diagnosis of hepatitis C is carried out in two steps:
1. A blood spot or saliva sample is tested for hepatitis C 
antibodies: if this test is positive, then the person has 
been in contact with the virus at some stage of their life.
2. A viral load test then looks for hepatitis C virus in the 
blood, and whether or not there is a chronic infection 
present and a person is contagious (in approximately  
20 percent of cases the infection spontaneously resolves 
and no further action is required).
 In order to improve hepatitis C awareness, each test  
should be conducted alongside information and 
counselling about how the virus is transmitted and how  
it can be prevented. 
 TESTING FOR HEPATITIS C
 Worldwide, 1.2 million people who inject drugs are 
estimated to have chronic hepatitis B.2 A safe, 
inexpensive and effective vaccination is available but 
the systematic discrimination and criminalisation of 
this population means that the availability and uptake 
of the hepatitis B vaccination remains poor.
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 Preventing Hepatitis C
 In 2012 the World Health Organization issued ‘Guidance 
on the Prevention of Viral Hepatitis B and C among 
People Who Inject Drugs’, which is based on a six-part 
framework of human rights, access to health care, 
access to justice, the acceptability of services to people 
who use drugs, health literacy and integrated service 
provision. The Guidance further endorses the evidence-
based package of harm reduction interventions for the 
fight against hepatitis B and C, HIV and tuberculosis 
– including needle and syringe programmes and opioid 
substitution therapy (both of which are also effective in 
preventing HIV transmission), targeted education, and the 
prevention, diagnosis and treatment of viral hepatitis.28
 As there is currently no vaccine against hepatitis C, the 
provision of sterile injecting equipment (both needles and 
syringes, but also other items such as filters, water and 
cookers) and opioid substitution therapy are the primary 
prevention measures that can disrupt the dominant route 
of transmission among people who inject drugs.40,41,42,43 
However, the coverage of these interventions needs to 
be much higher in the majority of countries. As such, 
countries with low (or no) coverage of these interventions 
should primarily concentrate on their urgent scale-up.44 
 Crucially, because of the scale of coverage required 
and similar routes of transmission, effective Hepatitis C 
prevention is also effective HIV prevention among people 
who inject drugs. 
 However, substantial reductions in hepatitis C transmission 
are unlikely to be achieved through these two interventions 
alone45 – the rapid scale up antiviral treatment is also 
required.46 As in the field of HIV, the topic of ‘treatment as 
prevention’ has also gained recent attention for hepatitis 
C: by scaling up treatment access the rate of transmission 
will be reduced as fewer individuals will be carrying active 
hepatitis C infections. Supervised drug consumption 
facilities, peer-based interventions, individual behavioural 
interventions, and voluntary testing and counselling are 
further evidence-based measures that have been shown to 
reduce injecting risk behaviour.47
 The effective delivery of evidence-based preventive  
measures will reduce hepatitis C infections, saving lives 
and money. The ‘war on drugs’ represents a major  
barrier to these interventions – resulting instead in  
increased stigma and fear, increased sharing of injecting 
equipment, increased infections, and reduced access to 
health care.48,13,16
8
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 Treatment of Hepatitis C
 Hepatitis C is a curable disease, but very few 
people who use drugs are allowed to access 
treatment.51,52,53,54,55 Evidence-based national guidelines 
for the management of hepatitis C are urgently 
needed in many countries to dispel the myths about 
treatment prospects for people who use drugs. For 
example, some health care providers continue to 
incorrectly assert that people who use drugs cannot 
manage the side effects of treatment, and that 
they will become re-infected with hepatitis C after 
treatment. Research has demonstrated that people 
who inject drugs can have treatment success rates 
that are similar to other patients.17 Some studies also 
have shown that re-infection rates after treatment 
can be low. Treating people who inject drugs can be 
especially cost-effective because of the greater public 
health benefits achieved through averting future 
infections.4 As with countless other factors such as 
housing status, alcohol use or mental health, drug use 
should never automatically exclude an individual from 
treatment. Instead, decisions must be made based  
on individual assessments.56
 If treatment access remains low, there will be a 
rising number of people who use drugs who develop 
advanced or fatal liver disease. On the other hand, 
scaling-up treatment will have a major impact on the 
prevalence of the disease – curing individuals who 
may have otherwise spread the virus, including people 
who continue to use drugs or who are at risk of 
relapse.46 As such, this is a highly cost-effective  
public health policy, especially when compared to 
offering no treatment or treating only those who do 
not inject drugs.57
 
9
 The standard hepatitis C treatment is a dual 
combination of ‘pegylated interferon’ (one injection 
per week) and ribavirin (one to three tablets, twice a 
day), although the exact treatment protocol will depend 
which genotype of the virus a person has. Depending 
on a range of factors, the duration of treatment varies 
from 12 to 72 weeks. These treatment regimens are 
challenging for all patients due to their side effects and 
the sheer length of treatment, but these issues can be 
managed through good clinical care.
 There are several new hepatitis C medicines in the 
development pipeline, with results from trials suggesting 
that more effective and better tolerated regimens should 
become available in the next few years. These treatment 
regimens will have the advantage of being tablet-only 
and not containing interferon. They will have fewer side 
effects and will require shorter treatment durations – 
making them easier to use. With these new medicines 
available, it has been claimed that hepatitis C could 
eventually be eliminated.58
 International recommendations for the management 
of hepatitis C among people who inject drugs are being 
developed by the World Health Organization and the 
International Network on Hepatitis care in Substance 
Users (INHSU).56 These will serve as a foundation for 
more specific guidelines to be adapted for the needs and 
contexts of individual countries.
 CURRENT AND FUTURE  
HEPATITIS C TREATMENTS
Left: Harm reduction activities among people who inject drugs: needle 
and syringe programmes and opioid substitution therapy in Ukraine. 
Photos by Efrem Lukatskiy & Natalia Kravchuk // courtesy of the 
International HIV/AIDS Alliance in Ukraine
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 When people who use drugs are living with hepatitis C, 
they can suffer a double stigma which deters them from 
testing, treatment and care, as well as from disclosing 
their hepatitis C status or injecting drug use to medical 
professionals.66 Addressing these issues is therefore 
a core part of an effective response to the hepatitis C 
epidemic among people who use drugs.
 Over time, hepatitis C has become increasingly associated 
with injecting drug use due to a global reduction in 
transmissions through medical practices and blood 
transfusions. There is therefore noticeably less sympathy 
for some people living with hepatitis C. This is associated 
with widespread perceptions of drug dependence as a 
weakness of character, a lack of responsibility or moral  
strength, or a ‘social evil’, rather than as a chronic relapsing 
disease. Where the ‘war on drugs’ is being fought, re-
pressive drug policies and the mass incarceration of people 
who use drugs are exacerbating these misconceptions. 
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 In Lithuania, more than 90 percent of people who inject 
drugs are living with the hepatitis C virus,2 and everyone 
receiving opioid substitution treatment is tested and 
referred to treatment if needed. The number of patients 
enrolled into hepatitis C treatment in this middle-income 
country has increased by 26 percent between 2008 and 
2011. Hepatitis C diagnostics and treatment are covered 
for those with mandatory health insurance,59 but 
‘pegylated interferon’ remains one of the government’s 
most costly medicines (the price of treatment decreased 
by only 3 percent between 2007 and 2011). However, 
people who inject drugs often do not have valid health 
insurance, are not aware of their hepatitis C status, and 
do not have access to either opioid substitution therapy 
or hepatitis C treatment.
 
 While Lithuania is a leading country in Eastern Europe 
in terms of the provision of hepatitis C treatment, only 
5 percent of those in need have been reached in recent 
years.59,60 The country’s response to the epidemic is 
being hindered by the low coverage of harm reduction 
interventions and an unfavourable policy environment 
for people who use drugs. There are nine needle and 
syringe programmes in Lithuania (funded primarily by 
local government), and 19 institutions offering opioid 
substitution therapy.61 Yet the coverage of these 
preventive measures is insufficient: an average of  
37 needles is distributed each year per person who 
injects drugs,62 and other injecting equipment (such 
as filters and water) is not provided. There are also key 
gaps at the national level in terms of hepatitis C testing 
and surveillance.
 HEPATITIS C IN LITHUANIA
 Awareness and Stigma
 Low awareness about hepatitis C – among the general 
population, policy makers, people who use drugs and 
health care professionals – remains a significant barrier 
to efficiently responding to this growing epidemic.63 
Knowledge about hepatitis C and the harms of undetected 
and untreated infections is poor, even for individuals living 
with the virus.64,65 For example, a recent study among 
people who inject drugs in Thailand revealed that two 
thirds of respondents did not seek hepatitis C testing 
because they had “never heard” of the virus.50 Reasons 
for this poor awareness include the lack of immediate 
symptoms, the slow progression of the disease, low 
political will to tackle the epidemic, the stigmatisation 
of people who use drugs, the lack of support for people 
living with hepatitis C, and the reliance on repressive drug 
control responses that prevent people who use drugs 
from accessing care and support. For many people who 
inject drugs, hepatitis C is almost viewed as a harm that 
cannot be avoided. 
2013 GCDP REPORT
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 The World Health Organization has referred to hepatitis 
C as a ‘viral time bomb’ due to the global human, social 
and economic costs that the epidemic threatens to 
inflict.33 In order to respond effectively and urgently 
to this threat, governments need to scale-up both 
prevention and treatment, especially for people who use 
drugs. This will require drug policy reform to create more 
enabling environments for public health approaches, the 
redirection of resources away from the ‘war on drugs’ 
and into health services, and widespread efforts to 
reduce the costs of treatment.
 Around the world, the high cost of hepatitis C treatment 
is having a devastating effect on its availability for 
people who use drugs. The manufacturers of the two 
patented forms of ‘pegylated interferon’ (Roche and 
Merck) charge different prices in different countries: the 
same medication can range in cost from US$ 2,000 to 
US$ 20,000 per treatment course of treatment.67 These 
patents are due to expire in the next two to four years. 
Hepatitis C diagnosis is relatively expensive too – with 
viral load tests costing between US$ 100 and US$ 200  
as they require specialist laboratory capacities.
 Yet hepatitis C has not received the widespread 
attention and international pressure – from governments, 
international donors, the United Nations and others 
– that has helped to dramatically reduce the price of 
antiretroviral therapy for HIV.68 Recent calls have been 
made for the World Health Organization to include 
hepatitis C treatments in their list of essential medicines, 
and also for UNITAID to include hepatitis C in its new 
four-year strategy in the hope that the organisation 
can replicate its significant impact in making HIV and 
tuberculosis treatments more affordable and accessible.69
 At the national level, treatment costs can be immediately 
reduced through active negotiations with pharmaceutical 
companies, alongside pressure from civil society and 
international organisations, to help lower prices and make 
treatment more accessible (including safe and effective 
generic versions of pegylated interferon).70   
 Even at current prices, however, hepatitis C treatment  
is cost-effective from a public health perspective due  
to the significant costs of treating liver disease caused  
by chronic, untreated infections. In the USA, for example, 
the one-off cost of hepatitis C treatment (between  
US$ 16,300 and US$ 32,700) is far exceeded by the  
cost of treating liver cancer (at an average of US$ 44,200 
per year).74
  With regards to the new hepatitis C medicines in the 
development pipeline, their use will be severely limited 
if they are not affordable for low and middle income 
countries. If negotiations with pharmaceutical companies 
do not lead to sufficient reductions in prices, countries 
should turn to the flexibilities that are permitted for 
public health emergencies as part of the World Trade 
Organization’s Agreement on Trade Related Aspects of 
Intellectual Property Rights (TRIPS).75 These include the 
issue of compulsory licenses for the import or production 
of cheaper generic or ‘biosimilar’ versions of these 
medicines, despite them being under patent. 
 Reducing the costs of existing and future hepatitis 
treatments should be an urgent priority for all national and 
international authorities.
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 Civil society organisations have advocated successfully 
for lower treatment prices and greater government 
commitments: for example, in Ukraine but also in India 
and Thailand. In Ukraine around 1 million people are 
living with hepatitis C, with more than 90 percent of 
people who inject drugs living with the virus. Similar 
to the situation faced by most other countries around 
the world, this means that the government cannot hope 
to meet the treatment need at current prices. As with 
many countries around the world, Ukraine still does 
not have an approved National Hepatitis Program or 
treatment protocol, and there are no official statistics 
collected about the virus.
 In response, civil society groups such as the 
International HIV/AIDS Alliance in Ukraine have reached 
an agreement with the Global Fund to Fight AIDS, 
Tuberculosis and Malaria to fund treatment for people 
who inject drugs – to be delivered alongside opioid 
substitution therapy and HIV treatments.71 The price for 
these treatments has been halved during negotiations 
with pharmaceutical companies.
 Civil society organisations in Ukraine have also played 
an important role in raising public awareness about 
hepatitis C, mobilising partners and communities, and 
facilitating dialogue between the government and the 
pharmaceutical industry. As a result, the Ukrainian 
President has instructed the government to find funds 
for hepatitis C treatment72 and the government has 
adopted a national viral hepatitis programme.73 
 ADVOCATING FOR MORE, CHEAPER TREATMENT: THE EXAMPLE OF UKRAINE
In April 2013, people living with 
hepatitis C and civil society 
groups including the Ukrainian 
Community Advisory Board (UCAB) 
demonstrated in front of the 
Cabinet of Ministers - one of many 
actions to get the government’s 
attention. This time their demands 
to approve a national hepatitis 
programme and fund hepatitis 
C treatment and other essential 
healthcare have been heard at 
least partially - the programme was 
approved soon afterward.  
Photo by Andriy Andrushkiv  // 
courtesy of All-Ukrainian Network 
of People Living with HIV and 
Ukrainian Community Advisory 
Board (UCAB)
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 The ‘war on drugs’ was made famous by US President 
Nixon more than 40 years ago, and has come to refer 
to a punitive, repressive law enforcement approach that 
takes a “zero tolerance” approach to drugs and seeks to 
achieve a drug-free world.76 This approach goes beyond 
the intention of current international drug policy treaties, 
which recognise concern for “the health and welfare of 
mankind” and allow for alternatives to criminalisation of 
drug users.77 The ‘war on drugs’ places people who use 
drugs within a criminal, rather than a public health, frame. 
With huge resources being invested in law enforcement 
around the world, this has translated into a war on people 
who use drugs and other vulnerable groups.
 The Global Commission on Drug Policy has previously 
outlined how this approach has failed to reduce the 
supply or use of drugs,76 as well as several ways in which 
the ‘war on drugs’ has driven the HIV pandemic among 
people who use drugs:
• Stigma and fear of arrest drive people who use drugs 
away from essential health services.
•  Health care systems limit access to care for people who 
use drugs, for example by setting arbitrary requirements 
around abstinence from drug use.
•  Restrictions on the provision of sterile needles and 
syringes results in increased rates of equipment  
sharing, exacerbated in many situations by the use of 
needle and syringe possession by police as evidence of 
criminal activity.
•  Prohibitions or restrictions on opioid substitution  
therapy and other evidence-based treatments result  
in avoidable harms.
•  The mass incarceration of this population places 
individuals in high-risk environments such as prisons  
and other closed settings.
•  At the same time, the lack of prevention measures in 
prison leads to avoidable virus outbreaks among people 
who use drugs.
•  Limited public funds continue to be wasted on  
harmful and ineffective drug law enforcement efforts 
instead of being invested in proven prevention and 
treatment strategies.78
 Each one of these factors is also driving hepatitis C 
transmission among people who use drugs. Indeed, 
as hepatitis C is more prevalent and contagious, the 
negative effects of drug policies are even more severe 
for this epidemic – further evidence that the ‘war on 
drugs’ has failed and serves only to generate harm while 
demonising and isolating those who are at risk. Hepatitis 
C among people who use drugs is preventable and 
treatable, but requires urgent drug policy reform. This 
chapter explores some of the specific ways in which the 
‘war on drugs’ fuels the hepatitis C epidemic, and the 
ways in which governments need to react.
 Political Ignorance of the Hepatitis C Epidemic
 The global hepatitis C pandemic continues to receive only 
a fraction of the attention, resources and commitment 
that its size and deadly consequences merit. Global 
access to hepatitis C treatment is far too low for people 
who use drugs, particularly in Eastern Europe, Central 
Asia, and Asia where the epidemic is at its worst among 
this population.
 Although public awareness is increasing, most  
governments around the world continue to overlook  
this important area of public health and the impacts of  
repressive drug policies. Population-based hepatitis  
surveillance is weak, and political efforts to secure effec-
tive prevention and affordable treatment lag far behind 
those for HIV. Existing harm reduction approaches need 
to be optimised and expanded in order to tackle hepatitis 
C – yet even among the leading harm reduction donors, 
hepatitis C is marginalised as a public health issue.
 Fear of Police and Stigma Drive Risks
 Those who operate and profit from the multi-billion 
dollar illicit drug market often remain out of the reach 
of law enforcement efforts. Instead, the ‘war on drugs’ 
persecutes people who use drugs and others from the 
lower levels of the drug trade. These individuals remain 
the easiest targets for law enforcement officers, whose 
performance is often evaluated based on arrest figures 
and who may seek to supplement income through  
bribes and extortion.
 HEPATITIS C AND  
THE ‘WAR ON DRUGS’
13
GLOBAL COMMISSION ON DRUG POLICY
 The emphasis on law enforcement leads to widespread 
fear of arrest and police harassment, but does not reduce 
drug use or demand. It simply serves to elevate the risks 
of hepatitis C and other preventable harms. The main 
outcome is that people who use drugs are driven away 
from essential public health services. For example, drug 
services are often targeted by police officers looking to 
quickly identify and harass people. This is particularly the 
case where laws prohibit the possession of needles and 
syringes, or where these items are used as evidence of 
criminal acts. People who use drugs may be unable or 
unwilling to access HIV or hepatitis prevention services, 
and instead will use potentially contaminated equipment.
 The ‘war on drugs’ also promotes the stigmatisation 
and discrimination of people who use drugs in a wide 
range of settings. For example, the ‘United Nations 
Special Rapporteur on torture and other cruel, inhuman 
or degrading treatment or punishment’ has reported that 
abuses faced by people who use drugs in health care 
settings “may cross a threshold of mistreatment that 
is tantamount to torture or cruel, inhuman or degrading 
treatment or punishment”.79 In many settings, people who 
use drugs are treated with suspicion and mistrust, and 
it is wrongly assumed that they will not succeed in their 
treatment unless they are abstinent from drugs.
 Mass Incarceration Fuels Transmission
 The failed ‘war on drugs’ has resulted in the mass 
incarceration of people who use drugs and other vulnerable 
individuals. As described earlier in this report, prisons are 
notoriously high-risk settings for the spread of HIV and 
hepatitis.80 Opioid substitution therapy and antiretroviral 
therapy are routinely denied to people in closed settings, 
as are evidence-based prevention tools including sterile 
injecting equipment and condoms. The issues are further 
exacerbated in compulsory detention centres for people 
who use drugs, which remain in operation as “treatment” 
in numerous countries despite widespread concerns about 
human rights.81
 Drugs remain widely available in prisons across the 
world, despite official denial of this fact by authorities. 
At the same time, there is often no access to harm 
reduction services. Of the 158 countries that have 
reported injecting drug use, just 10 provide needle and 
syringe programmes in prisons while only 41 countries 
provide prison-based opioid substitution therapy.3 The 
failure to provide services in closed settings impacts upon 
hepatitis treatment retention and success from the time 
of arrest. Governments should urgently develop policies 
to promote the health of people who use drugs inside 
custodial settings. At the same time, governments should 
scale-up policy alternatives to incarceration, including the 
decriminalisation of drug use and drug possession for 
personal use.
 Repressive Policies Prevent Service Access
 Many governments continue to prioritise punitive drug 
policies that impede the scale-up and coverage of harm 
reduction services for people who use drugs. Despite 
the wealth of evidence and technical guidance available 
to demonstrate the effectiveness and feasibility of harm 
reduction services, their global coverage is far too low. 
For example, needle and syringe programmes remain 
unavailable in more than 70 countries and territories 
where injecting drug use has been reported.3 The 
Russian Federation also continues to prohibit medicines 
used for opioid substitution therapy (methadone and 
buprenorphine), denying this proven intervention to more 
than 1.8 million people who inject drugs and with no signs 
of this position being reconsidered.
 Even when services are provided for people who use 
drugs, the constant threat of arrest and police harassment 
can impede adherence. Where hepatitis care is available 
to the general population, people who use drugs often 
face stigma and discrimination and are unable to access 
treatment. Care services are rarely adapted to their 
needs, despite the fact that people who use drugs can 
be successfully engaged in integrated, community based 
settings.82 Efforts to make services more user-friendly 
will increase uptake and engagement, which in turn 
will provide significant benefits in terms of hepatitis C 
prevention and averted disease burdens. However, the  
few targeted programmes for people who use drugs 
are often limited to small-scale ‘perpetual pilots’ that are 
dependent on external donors, as opposed to widely 
accessible, systematic initiatives. Governments need to 
invest more in efforts to prevent public health harms such 
as hepatitis C, rather than waste resources on repressive 
policies – which at best are ineffective, and at worst are 
exacerbating harms.
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 When drug policies are in line with public health goals, 
rather than striving in vain for a drug-free society, they 
can protect against hepatitis C transmission. Hepatitis C 
is preventable and curable – with evidence showing that 
people who use drugs are just as able to successfully 
complete treatment as other individuals.83
 We now have examples of successful, health-
based national programmes increasing awareness 
and consequently improving hepatitis C detection 
and treatment,49,84 such as the example from 
Scotland highlighted below. Studies have repeatedly 
demonstrated that public health and harm reduction 
approaches do not increase rates of drug use. Rather, 
they can reduce rates of drug use by creating enabling 
environments in which people can access health and 
drug dependence services without judgement  
or discrimination. 
 Despite the evidence, many governments continue to 
pursue counterproductive and ultimately futile efforts to 
eradicate the drug market. Drugs remain as affordable 
and widely available as ever. At the same time, our 
understanding of the negative consequences of the 
‘war on drugs’ continues to expand. Mass incarceration 
and punitive approaches prevent people who use drugs 
from accessing potentially lifesaving services, while 
the stigma, discrimination and abuses which these 
individuals face create high-risk environments for the 
transmission of hepatitis. 
 The silence about the harms produced by the ‘war 
on drugs’ has been broken, and there is now clear 
momentum toward reform as governments and the 
public begin to objectively critique existing policies 
and practices.85 There are a range of approaches and 
interventions available that have been proven to work, 
and these need to be scaled-up and further evaluated 
as a matter of urgency in order to reduce the negative 
impacts of punitive drug law enforcement. 
 Action is needed now.
Detention is used as drug 
‘treatment’ in Phnom Penh, 
Cambodia. This image is a still  
from the film ‘Violence Is Not The 
Solution’, used in the Campaign to 
Stop Torture in Health Care.
© Scott Anger and Bob Sacha for 
the Open Society Foundations
 PUBLIC HEALTH APPROACHES CAN  
SUPPRESS HARM: WHERE THEY ARE IGNORED,  
THE EPIDEMIC IS OUT OF CONTROL
GLOBAL COMMISSION ON DRUG POLICY16
FIGURE 2. 
Modelled number of 
people who inject drugs 
(PWID) with cirrhosis 
in Scotland by different 
uptake rates of 
hepatitis c treatment, 
2008-203088
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 Evidence-based national hepatitis C strategies have 
the potential to reduce the financial and societal 
burden of the epidemic. The Hepatitis C Action Plan 
for Scotland is an impressive example of a national 
strategy that has successfully focused on people  
who use drugs. Within a period of six years, hepatitis C 
testing, prevention and treatment have all  
been improved.
 The two-phase Action Plan was launched in 2006, 
and aimed to involve all stakeholders to build a strong 
governance structure. It explicitly acknowledged that 
people who inject drugs were the main group at risk of 
hepatitis C in the country, and focused the available 
resources accordingly. Key outcomes include:
• A four-fold to six-fold increase in the provision of 
sterile injecting equipment, including needles, syringes, 
filters and spoons.
•  An increase in the number of people tested for 
hepatitis C, mainly in prisons and drug services.
 BEST PRACTICE: THE NATIONAL HEPATITIS C ACTION 
PLAN IN SCOTLAND86
•  Increased awareness of hepatitis C due to a wide range 
of initiatives to promote testing.
•  A doubling of the number of people receiving hepatitis C 
treatment following the development of clinical services 
– including a large number of people who inject drugs.
•  An eight-fold increase in the number of prisoners 
receiving hepatitis C treatment.
•  A clear downward trend in the number of recent 
hepatitis C infections.
 As the Scottish Action Plan continues to be 
implemented and evaluated, further improvements in 
hepatitis C care and outcomes for people who use drugs 
are anticipated. For example, mathematical modelling 
has been used to predict the impact of hepatitis C 
treatment uptake on the number of liver cirrhosis and 
liver disease cases in Scotland. As the graph below 
shows, providing hepatitis C treatment to 2,000 people 
who inject drugs each year will prevent more than  
1,000 cases of liver cirrhosis by 2030.87
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 1. Break the taboo. Pursue an open debate and  
promote policies that effectively reduce consumption, 
and that prevent and reduce harms related to drug 
use and drug control policies. Increase investment 
in research and analysis into the impact of different 
policies and programs.
2. Replace the criminalization and punishment of people 
who use drugs with the offer of health and treatment 
services to those who need them.
3. Encourage experimentation by governments with  
models of legal regulation of drugs (with cannabis, for 
example) that are designed to undermine the power of 
organized crime and safeguard the health and security 
of their citizens.
4. Establish better metrics, indicators and goals to 
measure progress.
5. Challenge, rather than reinforce, common mis-
conceptions about drug markets, drug use and  
drug dependence.
6. Countries that continue to invest mostly in a law 
enforcement approach (despite the evidence) should 
focus their repressive actions on violent organized 
crime and drug traffickers, in order to reduce the harms 
associated with the illicit drug market.
7. Promote alternative sentences for small-scale  
and first-time drug dealers.
8. Invest more resources in evidence-based prevention, 
with a special focus on youth.
9. Offer a wide and easily accessible range of options 
for treatment and care for drug dependence, including 
substitution and heroin-assisted treatment, with 
special attention to those most at risk, including those 
in prisons and other custodial settings.
10. The United Nations system must provide leadership in 
the reform of global drug policy. This means promoting 
an effective approach based on evidence, supporting 
countries to develop drug policies that suit their 
context and meet their needs, and ensuring coherence 
among various UN agencies, policies and conventions.
11. Act urgently: The war on drugs has failed, and policies 
need to change now.
 RECOMMENDATIONS OF THE GLOBAL COMMISSION ON  
DRUG POLICY REPORT “WAR ON DRUGS” 
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 The following action must be taken by national 
leaders and the United Nations Secretary General, as 
well as the United Nations Office on Drugs and Crime, 
UNAIDS and the Commission on Narcotic Drugs:
1. Acknowledge and address the causal links between 
the war on drugs and the spread of HIV/AIDS, drug 
market violence and other health (e.g. hepatitis C) 
and social harms.
2. Respond to the fact that HIV risk behavior resulting 
from repressive drug control policies and under-
funding of evidence based approaches is the main 
issue driving the HIV epidemic in many regions of  
the world.
3. Push national governments to halt the practice of 
arresting and imprisoning people who use drugs but 
do no harm to others.
4. Replace ineffective measures focused on the 
criminalization and punishment of people who use 
drugs with evidence based and rights-affirming 
interventions proven to meaningfully reduce the 
negative individual and community consequences  
of drug use.
5. Countries that under-utilize proven public health 
measures should immediately scale up evidence-
based strategies to reduce HIV infection and protect 
the health of persons who use drugs, including 
sterile syringe distribution and other safer injecting 
programs. Failure to take these steps is criminal.
6. The public and private sectors should invest in an 
easily accessible range of evidence-based options 
for the treatment and care for drug dependence, 
including substitution and heroin-assisted treatment. 
These strategies reduce disease and death, and also 
limit the size and harmful consequences of drug 
markets by reducing the overall demand for drugs.
7. All authorities – from the municipal to international 
levels – must recognize the clear failure of the war 
on drugs to meaningfully reduce drug supply and, 
in doing so, move away from conventional measures 
of drug law enforcement “success” (e.g. arrests, 
seizures, convictions), which do not translate into 
positive effects in communities.
8. Measure drug policy success by indicators that have 
real meaning in communities such as reduced rates 
of transmission of HIV and other infectious diseases 
(e.g. hepatitis C), fewer overdose deaths, reduced 
drug market violence, fewer individuals incarcerated 
and lowered rates of problematic substance abuse.
9. Call for public health bodies within the United 
Nations system to lead the response to drug use 
and related harms and to promote evidence–based 
responses. Other bodies, including the International 
Narcotics Control Board, should be subjected to 
independent external review to ensure the policies 
they promote do not worsen community health  
and safety.
10. Act urgently: The war on drugs has failed, and 
millions of new HIV infections and AIDS deaths can 
be averted if action is taken now.
 RECOMMENDATIONS OF THE GLOBAL COMMISSION ON DRUG 
POLICY REPORT “THE WAR ON DRUGS AND HIV/AIDS” 
2012 GCDP REPORT
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 The purpose of the Global Commission on Drug  
Policy is to bring to the international level an informed,  
science-based discussion about humane and effective  
ways to reduce the harm caused by drugs to people  
and societies.
 
 GOALS 
• Review the basic assumptions, effectiveness and 
consequences of the ‘war on drugs’ approach
• Evaluate the risks and benefits of different national 
responses to the drug problem
• Develop actionable, evidence-based recommendations  
for constructive legal and policy reform 
 www.globalcommissionondrugs.org 
 
